Ultragenyx shares that GTX-102 trials will officially close on Oct 30, 2026.
Read the letter from Ultragenyx to the community: Angelman-Syndrome-Community-Update-9.16
Read the letter from Ultragenyx to the community: Angelman-Syndrome-Community-Update-9.16
Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.